| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Latigo Therapeutics auf der Jefferies Healthcare Conference: Strategiewechsel hin zur Kommerzialisierung im Schmerzmarkt | 3 | Investing.com Deutsch | ||
| 10.11. | Latigo Biotherapeutics auf Guggenheim-Konferenz: Schmerzmittel-Offensive gewinnt an Dynamik | 1 | Investing.com Deutsch | ||
| 05.11. | Latigo BioTherapeutics, Inc. GAAP EPS of -$0.55 beats by $0.12 | 1 | Seeking Alpha | ||
| 05.11. | Latigo Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Latigo Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| LATIGO BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.09. | Goldman Sachs reiterates Latigo Biotherapeutics stock buy rating | 1 | Investing.com | ||
| 03.09. | Latigo Biotherapeutics, Inc: Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | 282 | GlobeNewswire (Europe) | Completed upsized initial public offering, including full exercise of the underwriters' option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash... ► Artikel lesen | |
| 01.09. | Jefferies initiates Latigo Biotherapeutics stock with buy rating | 1 | Investing.com | ||
| 01.09. | Potenzial bei Schmerzmitteln: Goldman Sachs startet Latigo Biotherapeutics mit Kaufempfehlung | 3 | Investing.com Deutsch | ||
| 01.09. | Goldman Sachs initiates Latigo Biotherapeutics stock with buy rating on pain drug potential | 3 | Investing.com | ||
| 10.08. | Latigo Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 10.08. | Latigo Biotherapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.08. | Latigo Bio's IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs | 1 | MedCity News | ||
| 07.08. | Erfolgreiches Börsendebüt: Latigo Biotherapeutics Aktie steigt um 17 % | 1 | Investing.com Deutsch | ||
| 07.08. | Pain drug developer Latigo climbs after upsized IPO | 1 | Seeking Alpha | ||
| 07.08. | BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts | 1 | FierceBiotech | ||
| 07.08. | Latigo IPO raises nearly $350M for pain drug development | 1 | BioPharma Dive | ||
| 07.08. | Latigo Biotherapeutics prices upsized IPO at $18, the high end of the range | 2 | Renaissance Capital | ||
| 07.08. | Latigo Biotherapeutics prices IPO at $18 per share | 1 | Investing.com | ||
| 07.08. | Latigo Biotherapeutics, Inc: Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering | 296 | GlobeNewswire (Europe) | THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. ("Latigo"), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 82,62 | +11,11 % | RBC Capital downgrades CG Oncology stock rating on regulatory path | ||
| SUMMIT THERAPEUTICS | 11,680 | -17,40 % | Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback | ||
| QIAGEN | 45,310 | +0,13 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 307,48 | -6,16 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| ERASCA | 15,110 | -3,48 % | Erasca, Inc.: Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise | ||
| BEAM THERAPEUTICS | 20,800 | -8,89 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 3,290 | +14,43 % | Lexeo cardiomyopathy asset data prompts Street price target increases | ||
| ABSCI | 7,570 | -10,31 % | Absci Corp. (ABSI) Gets Downgraded. Here's How Much | ||
| KYMERA THERAPEUTICS | 125,00 | -2,02 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 2,905 | -8,79 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| ENLIVEN THERAPEUTICS | 47,870 | -1,93 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,960 | -7,72 % | Amylyx: Avexitide-Studie erreicht primären Endpunkt bei postbariatrischer Hypoglykämie | ||
| VIR BIOTECHNOLOGY | 9,640 | -3,31 % | Why Is Vir Biotechnology Stock Falling Friday? | ||
| TREVI THERAPEUTICS | 13,190 | -3,33 % | Trevi Therapeutics: Wie ein Nischenmedikament zum strategischen Hebel für den Milliardenmarkt Reizhusten werden könnte | Trevi Therapeutics steht kurz davor, mit Haduvio ein erstes Nischenprodukt in den US-Markt zu bringen und damit einen "specialty beachhead" zu etablieren, der als Plattform für eine mögliche Expansion... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 27,150 | -3,93 % | Arcutis Biotherapeutics legt Studiendaten zu Neurodermitis-Behandlung bei Säuglingen vor |